| 31.84 3.69 (13.11%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.7 |
1-year : | 44.03 |
| Resists | First : | 32.27 |
Second : | 37.7 |
| Pivot price | 29.88 |
|||
| Supports | First : | 28.16 |
Second : | 25.62 |
| MAs | MA(5) : | 29.48 |
MA(20) : | 29.92 |
| MA(100) : | 22.21 |
MA(250) : | 0 | |
| MACD | MACD : | 0.6 |
Signal : | 0.8  |
| %K %D | K(14,3) : | 49.1 |
D(3) : | 41.4 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 32.27 | Low : | 5.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ORKA ] has closed below upper band by 13.7%. Bollinger Bands are 15.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.29 - 32.5 | 32.5 - 32.69 |
| Low: | 27.67 - 27.91 | 27.91 - 28.13 |
| Close: | 31.42 - 31.85 | 31.85 - 32.24 |
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Sat, 20 Dec 2025
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Fri, 19 Dec 2025
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Fri, 19 Dec 2025
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3% - Here's What Happened - MarketBeat
Fri, 19 Dec 2025
Piper Sandler Upgrades Oruka Therapeutics (NASDAQ:ORKA) to Strong-Buy - MarketBeat
Sat, 13 Dec 2025
Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Thu, 11 Dec 2025
Oruka Therapeutics Announces New Board Member and Board Transition - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 95.1 (%) |
| Shares Short | 5,500 (K) |
| Shares Short P.Month | 5,210 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -90 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 3.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.19 |
| Dividend | 19.36 |
| Forward Dividend | 0 |
| Dividend Yield | 60.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|